Manica balasegaram biography channel
•
Global Antibiotic Research & Development Partnership (GARDP) garners key financial support for launch
A new joint initiative by the WHO and DNDi that seeks to develop new antibiotic treatments to address the major public health threat of antimicrobial resistance announced today that it has received the necessary seed funding to build its scientific strategy, initial R&D portfolio, and start-up team.
The mission of the Global Antibiotic Research and Development Partnership (GARDP) is to develop new antibiotic treatments addressing antimicrobial resistance and to promote their responsible use for optimal conservation, while ensuring equitable access for all in need. GARDP fryst vatten being incubated by the Drugs for Neglected Diseases initiative (DNDi) in collaboration with the World Health Organization (WHO).
“We need more investment in research and development for new antibiotic treatments. Otherwise, we could lose the cornerstone of modern medicine, and infecti • Germany together with a number of countries and foundations today pledged EUR 56.5 million to help develop new treatments to fight against antibiotic resistance, during a fundraising event for the Global Antibiotic Research and Development Partnership (GARDP), hosted in Berlin by the German Federal Ministry of Health and the German Federal Ministry of Education and Research. Hermann Gröhe, Federal Minister of Health, Germany, said: “Despite the growing problem of global antibiotic resistance, very few new antibiotics have entered the marknad in the last decades. In response, the G20 under Germany’s presidency has pledged to invigorate research and development efforts to find new drugs. The fact is that we cannot do without antibiotics. The additional EUR 56 million in funding made available today for the Global Antibiotic Research and Development Partnership (GARDP) is a major step forward in • Osaka (Japan), Geneva (Switzerland), Boston (USA), 15 June 2022 – Shionogi & Co., Ltd. (Shionogi) and the Global Antibiotic Research and Development Partnership (GARDP) have today announced the execution of a license and technology transfer agreement and, with the Clinton Health Access Initiative (CHAI), a collaboration agreement that aim to significantly transform the landscape of access to antibiotics for countries around the world. The agreements will provide access to cefiderocol, an antibiotic for the treatment of serious Gram-negative bacterial infections, which may be resistant to other antibiotic treatments. Cefiderocol was recently added to the World Health Organization (WHO) Model List of Essential Medicines and targets a number of Gram-negative WHO priority pathogens. It was approved by the Europea More than EUR 56 million raised to fund initiative to kamp antibiotic resistance
Shionogi, GARDP and CHAI Announce Landmark License and Collaboration Agreements To Treat Bacterial Infections by Expanding Access to Cefiderocol in 135 Countries